JALIMA PHARMA
0824.690.634 · rovalta.com · 23/09/2026
NORMAL SITUATION
JALIMA PHARMA
Financial year 2025 · closed on 30/09/2025
Net result
21,3 k €
-33.7% YoY
Gross margin
-25 k €
-32.7% YoY
Equity
232 k €
-20.4% YoY
Company — Normal situation.
Overview
What does JALIMA PHARMA do?
JALIMA PHARMA is a company registered in Belgium.
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0824.690.634
Legal form
Private limited company
Contributed capital
18 600,00 €
Latest accounts
30/09/2025
Signals
ProfitableSolid equityGood liquidityPositive cashflow
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 15 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||
| Gross margin | -25 k € | -32.7% | -18,8 k € | -271% | 11 k € | -60.0% | 27,5 k € | -60.8% | 70,1 k € | -50.3% | 141,1 k € | +53.0% | 92,2 k € | +10.4% | 83,5 k € | +98.2% | 42,1 k € | +646% | 5,7 k € | -87.2% | 44,3 k € | -2.2% | 45,3 k € | -16.8% | 54,4 k € | -55.7% | 122,7 k € | -20.9% | 155,1 k € |
| EBITDA | -26,2 k € | -31.0% | -20 k € | -307% | 9,7 k € | -62.9% | 26,2 k € | -61.8% | 68,6 k € | -50.9% | 139,7 k € | +54.4% | 90,5 k € | +12.1% | 80,7 k € | +96.2% | 41,1 k € | +1107% | 3,4 k € | -91.1% | 38,4 k € | -12.5% | 43,9 k € | -9.1% | 48,3 k € | -59.6% | 119,7 k € | -21.6% | 152,6 k € |
| Operating result | -26,2 k € | +3.9% | -27,3 k € | -2263% | 1,3 k € | -88.7% | 11,2 k € | -78.3% | 51,5 k € | -57.8% | 122 k € | +76.4% | 69,2 k € | +18.2% | 58,5 k € | +160% | 22,5 k € | +247% | -15,3 k € | -192% | 16,6 k € | -36.9% | 26,4 k € | -20.3% | 33,1 k € | -68.8% | 105,9 k € | -20.6% | 133,3 k € |
| Net result | 21,3 k € | -33.7% | 32,1 k € | +105% | 15,7 k € | +128% | -55,4 k € | -146% | 120,1 k € | +49.3% | 80,4 k € | -5.5% | 85,2 k € | +158% | 33 k € | +0.5% | 32,8 k € | +41.2% | 23,2 k € | -23.2% | 30,3 k € | +0.8% | 30 k € | -19.5% | 37,3 k € | -48.8% | 72,9 k € | -13.0% | 83,8 k € |
| Balance sheet | |||||||||||||||||||||||||||||
| Equity | 232 k € | -20.4% | 291,4 k € | +2.5% | 284,3 k € | +5.8% | 268,6 k € | -35.0% | 413,3 k € | +40.9% | 293,3 k € | +20.6% | 243,1 k € | +29.0% | 188,4 k € | -35.1% | 290,4 k € | +12.7% | 257,6 k € | +9.9% | 234,4 k € | +14.8% | 204,1 k € | -2.4% | 209,1 k € | +21.7% | 171,8 k € | +67.8% | 102,4 k € |
| Total assets | 236,6 k € | -33.6% | 356,2 k € | -5.2% | 375,6 k € | +0.9% | 372,2 k € | -12.1% | 423,5 k € | +12.6% | 376,1 k € | +33.3% | 282,2 k € | +30.7% | 215,9 k € | -30.1% | 308,8 k € | +16.6% | 264,8 k € | +2.3% | 258,8 k € | +13.3% | 228,5 k € | -19.5% | 283,9 k € | +7.8% | 263,4 k € | +49.5% | 176,1 k € |
| Cash | 235,4 k € | +4614% | 5 k € | +93.5% | 2,6 k € | -17.0% | 3,1 k € | -29.5% | 4,4 k € | +16.0% | 3,8 k € | -94.7% | 72,1 k € | +753% | 8,5 k € | -93.4% | 127,7 k € | +639% | 17,3 k € | -7.6% | 18,7 k € | -38.1% | 30,2 k € | -83.0% | 177,4 k € | +6.4% | 166,8 k € | +61.4% | 103,3 k € |
| Debts | 4,6 k € | -92.9% | 64,4 k € | -29.1% | 90,8 k € | -11.7% | 102,9 k € | +1092% | 8,6 k € | -89.4% | 81,1 k € | +110% | 38,6 k € | +41.3% | 27,3 k € | +49.8% | 18,2 k € | +175% | 6,6 k € | -71.6% | 23,4 k € | +5.3% | 22,2 k € | -69.3% | 72,3 k € | -19.8% | 90 k € | +24.5% | 72,3 k € |
| Other | |||||||||||||||||||||||||||||
| Workforce | – | – | – | – | – | – | – | – | – | 0,1 ETP | -50.0% | 0,2 ETP | – | 0,3 ETP | +200% | 0,1 ETP | – | ||||||||||||
Governance
Board of directors
Seen on filing of 30/09/2025 · 2 active · 5 ended
Active mandates
Carine De Vroe
ActiveLieven Baert
ActiveEnded mandates
Carine De Vroe
EndedCarine De Vroe
EndedLieven Baert
EndedLieven Baert
EndedFinancials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/10/2024 | 01/10/2023 | 01/10/2022 | 01/10/2021 | 01/10/2020 | 01/10/2019 |
| Closing of the financial year | 30/09/2025 | 30/09/2024 | 30/09/2023 | 30/09/2022 | 30/09/2021 | 30/09/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 09/12/2025 | 17/01/2025 | 02/04/2024 | 03/04/2023 | 28/03/2022 | 29/03/2021 |
| General meeting | 28/11/2025 | 23/12/2024 | 29/03/2024 | 31/03/2023 | 25/03/2022 | 26/03/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
15 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 30/09/2025 | 28/11/2025 | 09/12/2025 | Dutch | |
| Micro model | 30/09/2024 | 23/12/2024 | 17/01/2025 | Dutch | |
| Micro model | 30/09/2023 | 29/03/2024 | 02/04/2024 | Dutch | |
| Micro model | 30/09/2022 | 31/03/2023 | 03/04/2023 | Dutch | |
| Micro model | 30/09/2021 | 25/03/2022 | 28/03/2022 | Dutch | |
| Micro model | 30/09/2020 | 26/03/2021 | 29/03/2021 | Dutch | |
| Micro model | 30/09/2019 | 27/03/2020 | 03/04/2020 | Dutch | |
| Micro model | 30/09/2018 | 29/03/2019 | 04/04/2019 | Dutch | |
| Micro model | 30/09/2017 | 30/03/2018 | 03/04/2018 | Dutch | |
| Abridged model | 30/09/2016 | 31/03/2017 | 31/03/2017 | Dutch | |
| Abridged model | 30/09/2015 | 25/03/2016 | 30/03/2016 | Dutch | |
| Abridged model | 30/09/2014 | 30/12/2014 | 31/03/2015 | Dutch | |
| Abridged model | 30/09/2013 | 29/03/2014 | 28/04/2014 | Dutch | |
| Abridged model | 30/09/2012 | 30/03/2013 | 30/04/2013 | Dutch | |
| Abridged model | 30/09/2011 | 30/03/2012 | 30/05/2012 | Dutch |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 30/09/2025 · 2 active · 5 ended
Active mandates
Carine De Vroe
ActiveLieven Baert
ActiveEnded mandates
Carine De Vroe
EndedCarine De Vroe
EndedLieven Baert
EndedLieven Baert
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 202521,3 k €↓
- 2024Annual accounts 202432,1 k €↑
- 2023Annual accounts 202315,7 k €↑
- 2022Annual accounts 2022-55,4 k €↓
- 2021Annual accounts 2021120,1 k €↑
- 2020Annual accounts 202080,4 k €↓
- 2019Annual accounts 201985,2 k €↑
- 2018Annual accounts 201833 k €↑
- 2017Annual accounts 201732,8 k €↑
- 2016Annual accounts 201623,2 k €↓
- 2015Annual accounts 201530,3 k €↑
- 2014Annual accounts 201430 k €↓
- 2013Annual accounts 201337,3 k €↓
- 2012Annual accounts 201272,9 k €↓
- 2011Annual accounts 201183,8 k €